GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroMetrix Inc (NAS:NURO) » Definitions » Debt-to-Revenue

NURO (NeuroMetrix) Debt-to-Revenue : 0.06 (As of Sep. 2024)


View and export this data going back to 2004. Start your Free Trial

What is NeuroMetrix Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

NeuroMetrix's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.14 Mil. NeuroMetrix's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.00 Mil. NeuroMetrix's annualized Revenue for the quarter that ended in Sep. 2024 was $2.35 Mil. NeuroMetrix's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 0.06.


NeuroMetrix Debt-to-Revenue Historical Data

The historical data trend for NeuroMetrix's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroMetrix Debt-to-Revenue Chart

NeuroMetrix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 0.14 0.07 0.04 0.04

NeuroMetrix Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.05 0.05 0.06 0.06

Competitive Comparison of NeuroMetrix's Debt-to-Revenue

For the Medical Devices subindustry, NeuroMetrix's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuroMetrix's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NeuroMetrix's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where NeuroMetrix's Debt-to-Revenue falls into.



NeuroMetrix Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

NeuroMetrix's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.148 + 0.092) / 5.901
=0.04

NeuroMetrix's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.143 + 0) / 2.348
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.


NeuroMetrix Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of NeuroMetrix's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuroMetrix Business Description

Traded in Other Exchanges
N/A
Address
4B Gill Street, Woburn, MA, USA, 01801
NeuroMetrix Inc is a commercial-stage healthcare company. Its core business activities are integrated with in-house capabilities spanning product development, manufacturing, regulatory affairs and compliance, sales and marketing, and customer support. The company produces bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The product line of the company includes Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The company operates in a single segment being Medical equipment and consumables.
Executives
Bradley M Fluegel director 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Thomas T Higgins officer: Chief Financial Officer
Topline Capital Management, Llc other: See Explanation in Footnotes 544 EUCLID STREET, SANTA MONICA CA 90402
Topline Capital Partners, Lp 10 percent owner 544 EUCLID STREET, SANTA MONICA CA 90402
Mcbirney Collin other: See Explanation in Footnotes 544 EUCLID STREET, SANTA MONICA CA 90402
Shai Gozani director, officer: Chairman, President and CEO C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Francis X Mcgillin officer: Senior VP, Consumer C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Avermaete David Van director C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Krishnamurthy Balachandran officer: S. VP and GM, International C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Nancy E Katz director CALYPTE BIOMEDICAL CORP, 1265 HARBOR BAY PKWY, ALAHEDA CA 94502
Neurometrix Inc officer: Senior Vice President & GM
Walter Christensen officer: Sr. VP, Global Sales C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Timothy R Surgenor director 100 FOXBOROUGH BOULEVARD, SUITE 240, FOXBOROUGH MA 02035
Deerfield Management Company, L.p. (series C) 10 percent owner 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p. 10 percent owner 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017

NeuroMetrix Headlines

From GuruFocus

NeuroMetrix Reports Q1 2024 Business Highlights

By Marketwired 05-15-2024

Q2 2020 NeuroMetrix Inc Earnings Call Transcript

By GuruFocus Research 02-08-2024

Q3 2021 NeuroMetrix Inc Earnings Call Transcript

By GuruFocus Research 02-08-2024

Q2 2022 NeuroMetrix Inc Earnings Call Transcript

By GuruFocus Research 02-08-2024

Q2 2021 NeuroMetrix Inc Earnings Call Transcript

By GuruFocus Research 02-08-2024

Q1 2022 NeuroMetrix Inc Earnings Call Transcript

By GuruFocus Research 02-08-2024

Q1 2020 NeuroMetrix Inc Earnings Call Transcript

By GuruFocus Research 02-08-2024